The prevailing therapeutic approach to wet AMD in clinical settings primarily aims to mitigate pathological neovascularization, principally through intravitreal administration of anti-vascular endothelial growth factor (VEGF) biologics such as ranibizumab [7], bevacizumab [8], and aflibercept [9], which have demonstrated substantial efficacy. The gene discussed is VEGFA; the disease is age-related macular degeneration.